Cardiovascular Complications of Prostate Cancer Therapy

Courtney M. Campbell, Kathleen W. Zhang, Andrew Collier, Mark Linch, Adam C. Calaway, Lee Ponsky, Avirup Guha, Arjun K. Ghosh

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Purpose of review: With treatment advances, the most common cause of death in prostate cancer patients is cardiovascular disease. Discerning the contribution of prostate cancer treatment on cardiovascular complications versus the natural progression of cardiovascular disease remains an ongoing area of investigation. Evaluating the research and identifying opportunities for further investigation is critical for optimal care of this prostate cancer patient population. Recent findings: The degree that hormone therapy contributes to cardiovascular morbidity and mortality remains uncertain with conflicting results from large meta-analyses. Underlying cardiovascular disease or multiple cardiovascular disease risk factors appear to compound the risk of adverse events. Drug-specific cardiotoxicity in prostate cancer treatment has not been fully delineated. Recent studies have suggested the potential for wide-ranging prostate cancer cardiotoxic effects, including atherosclerosis acceleration, myocardial infarction, cardiomyopathy, hypertension, arrhythmias, and stroke along with other thromboembolic diseases. Summary: This review provides an overview of prostate cancer treatment, a comprehensive analysis of the literature linking androgen deprivation therapy and cardiovascular disease, a discussion of cardiovascular risk management and mitigation in prostate cancer patients, and an exploration of research opportunities within cardio-oncology for prostate cancer.

Original languageEnglish (US)
Article number69
JournalCurrent Treatment Options in Cardiovascular Medicine
Issue number12
StatePublished - Dec 2020
Externally publishedYes


  • Androgen deprivation therapy
  • Androgen receptor blockade
  • Arrhythmia
  • Cardio-oncology
  • Cardiovascular disease
  • Gonado-tropin-releasing hormone antagonist
  • Gonadotropin-releasing hormone agonist
  • Hormone therapy
  • Hypertension
  • Myocardial infarction
  • Prostate cancer
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Cardiovascular Complications of Prostate Cancer Therapy'. Together they form a unique fingerprint.

Cite this